Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 3Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 428Neoplasms 296Breast Neoplasms 296Colorectal Neoplasms 241Neoplasm Metastasis 196Ovarian Neoplasms 171Lung Neoplasms 149Recurrence 148Prostatic Neoplasms 146Pancreatic Neoplasms 141Multiple Myeloma 136Stomach Neoplasms 129Squamous Cell Carcinoma of Head and Neck 128Melanoma 123Leukemia, Myeloid, Acute 115Endometrial Neoplasms 114Advanced Solid Tumors 113Advanced Solid Tumor 108Carcinoma, Hepatocellular 102Triple Negative Breast Neoplasms 101Small Cell Lung Carcinoma 88Uterine Cervical Neoplasms 86Lymphoma, Non-Hodgkin 83Carcinoma, Renal Cell 72Lymphoma, Follicular 71Lymphoma 67Leukemia, Lymphocytic, Chronic, B-Cell 65Solid Tumor 64Lymphoma, Large B-Cell, Diffuse 64Hematologic Neoplasms 61

Interventions

beta-D-glucosylisophosphoramide mustard 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × INDUSTRY × Metastatic Pancreatic Adenocarcinoma × Clear all
NCT01954992 2024-12-31

Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer

Eleison Pharmaceuticals LLC.

Phase 3 Recruiting
480 enrolled
Gastrointestinal

Metastatic Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡